The rights issue and over-allotment issue in Cereno Scientific AB is registered

Report this content

On June 7, Cereno Scientific AB completed its rights issue, which was oversubscribed and provided the company approximately SEK 55.6 million before issue costs. Furthermore, the accompanying over-allotment issue was fully utilized and provided the company with an additional SEK 5.0 million before issue costs.

The rights issue was registered by the Swedish Companies Registration Office on July 3, 2019. Therefore, paid subscribed shares (BTA) will be deregistered and replaced by new shares. The last day for trading with BTA at Spotlight Stock Market is July 10, 2019. The new shares are expected to be available on each VP account and depot on July 16, 2019.

The over-allotment issue of 1,724,137 shares of series B, which was published on June 13 and which provided Cereno Scientific with SEK 5 million, was registered by the Swedish Companies Registration Office on 5 July 2019.

Through the rights issue and the over-allotment issue, the number of shares in Cereno Scientific has increased by 20 905 439 shares of series B to a total of 40 086 741, of which 722 248 are shares of series A and 39 364 493 are shares of series B. The share capital has increased by 2,090,543.9 SEK 4,008,674.1.

When the remuneration issue of 132,571 series B shares, which was published on June 28, has been registered with the Swedish Companies Registration Office, the number of shares will increase by an additional 132,571 shares of series B to a total of 40,219,312 shares, of which 722,248 are shares of series A and 39,497 064 are shares of series B. Therefore, the share capital will increase by an additional SEK 13,257.1 to a total of SEK 4,021,931.2.


Mangold Fondkommission AB and MAQS Advokatbyrå acted as financial adviser and legal adviser in the rights issue.

For further information, please contact: 

Daniel Brodén  – CFO
Tel: +46 768 66 77 87

About Cereno Scientific AB 
Cereno Scientific is developing novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. In parallel with the development of CS1, Cereno Scientific develops CS014, a preclinical phase compound with promising and innovative characteristics in cardiovascular diseases. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.


Documents & Links